Loading…
FOLFIRI Combined with Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer Patients with Hyperbilirubinemia after UGT1A1 Genotyping
Objective: To report a metastatic colorectal cancer patient with hyperbilirubinemia treated with a combination of bevacizumab and FOLFIRI (5-fluorouracil, leucovorin, and irinotecan) using uridine diphosphate glucuronosyl transferase (UGT1A1) genotyping. Clinical Presentation and Intervention: A 46-...
Saved in:
| Published in: | Medical principles and practice 2014-01, Vol.23 (5), p.478-481 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c494t-ebeb719198bf0a78ac39465fbf5441e9271e4f1decff2f03ee2c7a37bbeb71c23 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c494t-ebeb719198bf0a78ac39465fbf5441e9271e4f1decff2f03ee2c7a37bbeb71c23 |
| container_end_page | 481 |
| container_issue | 5 |
| container_start_page | 478 |
| container_title | Medical principles and practice |
| container_volume | 23 |
| creator | Yeh, Yung-Sung Huang, Meng-Lin Chang, Se-Fen Chen, Chin-Fan Hu, Huang-Ming Wang, Jaw-Yuan |
| description | Objective: To report a metastatic colorectal cancer patient with hyperbilirubinemia treated with a combination of bevacizumab and FOLFIRI (5-fluorouracil, leucovorin, and irinotecan) using uridine diphosphate glucuronosyl transferase (UGT1A1) genotyping. Clinical Presentation and Intervention: A 46-year-old male was diagnosed with rectosigmoid colon cancer with liver metastases and hyperbilirubinemia presenting with severe jaundice. UGT1A1 genotyping was used before therapy to ascertain whether genotype-adjusted dosages of irinotecan plus bevacizumab could alleviate the toxicity. Then, the patient was treated with FOLFIRI. Conclusion: The FOLFIRI regimen was successfully used in this patient without concerns regarding toxicity. |
| doi_str_mv | 10.1159/000358799 |
| format | article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5586907</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>24642571</sourcerecordid><originalsourceid>FETCH-LOGICAL-c494t-ebeb719198bf0a78ac39465fbf5441e9271e4f1decff2f03ee2c7a37bbeb71c23</originalsourceid><addsrcrecordid>eNptkU1rGzEQhkVpaD7aQ--lCHrKYVNpV2utLoXExI7BIaY452Ukjxy1-4Ukpzh_o3-4Sjc1LfQkMfPM8w4MIe85u-C8VJ8ZY0VZSaVekRMu8iJjvOSv059xnslS8mNyGsK3hFVFwd6Q41xMRJ7qJ-Tn7G45W3xd0Gnfatfhhv5w8YFe4SMY97RrQVMIdOZ8iNky9enaI8QWu0ht7-ktRggRojNJ0PQeTYSGTqEz6Okq1RMYRuXNfkCvXeP87jmodUDBxoTdz9f8ktM5dn3cD67bviVHFpqA717eM3I_u15Pb7Ll3XwxvVxmRigRM9SoJVdcVdoykBWYQolJabUtheCocslRWL5BY21uWYGYGwmF1L_nTF6ckS-jd9jpFjcm7eqhqQfvWvD7ugdX_9vp3EO97R_rsqwmiskkOB8FxvcheLSHWc7q58vUh8sk9uPfYQfyzykS8GkEvoPfoj8At6vVqKiHjU3Uh_9SLym_ANaaofw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>FOLFIRI Combined with Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer Patients with Hyperbilirubinemia after UGT1A1 Genotyping</title><source>PubMed Central</source><source>Karger Open Access</source><creator>Yeh, Yung-Sung ; Huang, Meng-Lin ; Chang, Se-Fen ; Chen, Chin-Fan ; Hu, Huang-Ming ; Wang, Jaw-Yuan</creator><creatorcontrib>Yeh, Yung-Sung ; Huang, Meng-Lin ; Chang, Se-Fen ; Chen, Chin-Fan ; Hu, Huang-Ming ; Wang, Jaw-Yuan</creatorcontrib><description>Objective: To report a metastatic colorectal cancer patient with hyperbilirubinemia treated with a combination of bevacizumab and FOLFIRI (5-fluorouracil, leucovorin, and irinotecan) using uridine diphosphate glucuronosyl transferase (UGT1A1) genotyping. Clinical Presentation and Intervention: A 46-year-old male was diagnosed with rectosigmoid colon cancer with liver metastases and hyperbilirubinemia presenting with severe jaundice. UGT1A1 genotyping was used before therapy to ascertain whether genotype-adjusted dosages of irinotecan plus bevacizumab could alleviate the toxicity. Then, the patient was treated with FOLFIRI. Conclusion: The FOLFIRI regimen was successfully used in this patient without concerns regarding toxicity.</description><identifier>ISSN: 1011-7571</identifier><identifier>EISSN: 1423-0151</identifier><identifier>DOI: 10.1159/000358799</identifier><identifier>PMID: 24642571</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Adenocarcinoma - drug therapy ; Adenocarcinoma - genetics ; Adenocarcinoma - secondary ; Angiogenesis Inhibitors - administration & dosage ; Antibodies, Monoclonal, Humanized - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Bevacizumab ; Camptothecin - analogs & derivatives ; Camptothecin - therapeutic use ; Case Report ; Colorectal Neoplasms - drug therapy ; Colorectal Neoplasms - genetics ; Colorectal Neoplasms - pathology ; Fluorouracil - therapeutic use ; Genotype ; Glucuronosyltransferase - genetics ; Humans ; Hyperbilirubinemia - complications ; Hyperbilirubinemia - genetics ; Leucovorin - therapeutic use ; Liver Neoplasms - drug therapy ; Liver Neoplasms - genetics ; Liver Neoplasms - secondary ; Male ; Middle Aged</subject><ispartof>Medical principles and practice, 2014-01, Vol.23 (5), p.478-481</ispartof><rights>2014 S. Karger AG, Basel</rights><rights>2014 S. Karger AG, Basel.</rights><rights>Copyright © 2014 by S. Karger AG, Basel 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c494t-ebeb719198bf0a78ac39465fbf5441e9271e4f1decff2f03ee2c7a37bbeb71c23</citedby><cites>FETCH-LOGICAL-c494t-ebeb719198bf0a78ac39465fbf5441e9271e4f1decff2f03ee2c7a37bbeb71c23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586907/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586907/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,733,786,790,891,27668,27957,27958,53827,53829</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24642571$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yeh, Yung-Sung</creatorcontrib><creatorcontrib>Huang, Meng-Lin</creatorcontrib><creatorcontrib>Chang, Se-Fen</creatorcontrib><creatorcontrib>Chen, Chin-Fan</creatorcontrib><creatorcontrib>Hu, Huang-Ming</creatorcontrib><creatorcontrib>Wang, Jaw-Yuan</creatorcontrib><title>FOLFIRI Combined with Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer Patients with Hyperbilirubinemia after UGT1A1 Genotyping</title><title>Medical principles and practice</title><addtitle>Med Princ Pract</addtitle><description>Objective: To report a metastatic colorectal cancer patient with hyperbilirubinemia treated with a combination of bevacizumab and FOLFIRI (5-fluorouracil, leucovorin, and irinotecan) using uridine diphosphate glucuronosyl transferase (UGT1A1) genotyping. Clinical Presentation and Intervention: A 46-year-old male was diagnosed with rectosigmoid colon cancer with liver metastases and hyperbilirubinemia presenting with severe jaundice. UGT1A1 genotyping was used before therapy to ascertain whether genotype-adjusted dosages of irinotecan plus bevacizumab could alleviate the toxicity. Then, the patient was treated with FOLFIRI. Conclusion: The FOLFIRI regimen was successfully used in this patient without concerns regarding toxicity.</description><subject>Adenocarcinoma - drug therapy</subject><subject>Adenocarcinoma - genetics</subject><subject>Adenocarcinoma - secondary</subject><subject>Angiogenesis Inhibitors - administration & dosage</subject><subject>Antibodies, Monoclonal, Humanized - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Bevacizumab</subject><subject>Camptothecin - analogs & derivatives</subject><subject>Camptothecin - therapeutic use</subject><subject>Case Report</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>Colorectal Neoplasms - genetics</subject><subject>Colorectal Neoplasms - pathology</subject><subject>Fluorouracil - therapeutic use</subject><subject>Genotype</subject><subject>Glucuronosyltransferase - genetics</subject><subject>Humans</subject><subject>Hyperbilirubinemia - complications</subject><subject>Hyperbilirubinemia - genetics</subject><subject>Leucovorin - therapeutic use</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - genetics</subject><subject>Liver Neoplasms - secondary</subject><subject>Male</subject><subject>Middle Aged</subject><issn>1011-7571</issn><issn>1423-0151</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>M--</sourceid><recordid>eNptkU1rGzEQhkVpaD7aQ--lCHrKYVNpV2utLoXExI7BIaY452Ukjxy1-4Ukpzh_o3-4Sjc1LfQkMfPM8w4MIe85u-C8VJ8ZY0VZSaVekRMu8iJjvOSv059xnslS8mNyGsK3hFVFwd6Q41xMRJ7qJ-Tn7G45W3xd0Gnfatfhhv5w8YFe4SMY97RrQVMIdOZ8iNky9enaI8QWu0ht7-ktRggRojNJ0PQeTYSGTqEz6Okq1RMYRuXNfkCvXeP87jmodUDBxoTdz9f8ktM5dn3cD67bviVHFpqA717eM3I_u15Pb7Ll3XwxvVxmRigRM9SoJVdcVdoykBWYQolJabUtheCocslRWL5BY21uWYGYGwmF1L_nTF6ckS-jd9jpFjcm7eqhqQfvWvD7ugdX_9vp3EO97R_rsqwmiskkOB8FxvcheLSHWc7q58vUh8sk9uPfYQfyzykS8GkEvoPfoj8At6vVqKiHjU3Uh_9SLym_ANaaofw</recordid><startdate>20140101</startdate><enddate>20140101</enddate><creator>Yeh, Yung-Sung</creator><creator>Huang, Meng-Lin</creator><creator>Chang, Se-Fen</creator><creator>Chen, Chin-Fan</creator><creator>Hu, Huang-Ming</creator><creator>Wang, Jaw-Yuan</creator><general>S. Karger AG</general><scope>M--</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20140101</creationdate><title>FOLFIRI Combined with Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer Patients with Hyperbilirubinemia after UGT1A1 Genotyping</title><author>Yeh, Yung-Sung ; Huang, Meng-Lin ; Chang, Se-Fen ; Chen, Chin-Fan ; Hu, Huang-Ming ; Wang, Jaw-Yuan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c494t-ebeb719198bf0a78ac39465fbf5441e9271e4f1decff2f03ee2c7a37bbeb71c23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Adenocarcinoma - genetics</topic><topic>Adenocarcinoma - secondary</topic><topic>Angiogenesis Inhibitors - administration & dosage</topic><topic>Antibodies, Monoclonal, Humanized - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Bevacizumab</topic><topic>Camptothecin - analogs & derivatives</topic><topic>Camptothecin - therapeutic use</topic><topic>Case Report</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>Colorectal Neoplasms - genetics</topic><topic>Colorectal Neoplasms - pathology</topic><topic>Fluorouracil - therapeutic use</topic><topic>Genotype</topic><topic>Glucuronosyltransferase - genetics</topic><topic>Humans</topic><topic>Hyperbilirubinemia - complications</topic><topic>Hyperbilirubinemia - genetics</topic><topic>Leucovorin - therapeutic use</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - genetics</topic><topic>Liver Neoplasms - secondary</topic><topic>Male</topic><topic>Middle Aged</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yeh, Yung-Sung</creatorcontrib><creatorcontrib>Huang, Meng-Lin</creatorcontrib><creatorcontrib>Chang, Se-Fen</creatorcontrib><creatorcontrib>Chen, Chin-Fan</creatorcontrib><creatorcontrib>Hu, Huang-Ming</creatorcontrib><creatorcontrib>Wang, Jaw-Yuan</creatorcontrib><collection>Karger Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medical principles and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yeh, Yung-Sung</au><au>Huang, Meng-Lin</au><au>Chang, Se-Fen</au><au>Chen, Chin-Fan</au><au>Hu, Huang-Ming</au><au>Wang, Jaw-Yuan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>FOLFIRI Combined with Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer Patients with Hyperbilirubinemia after UGT1A1 Genotyping</atitle><jtitle>Medical principles and practice</jtitle><addtitle>Med Princ Pract</addtitle><date>2014-01-01</date><risdate>2014</risdate><volume>23</volume><issue>5</issue><spage>478</spage><epage>481</epage><pages>478-481</pages><issn>1011-7571</issn><eissn>1423-0151</eissn><abstract>Objective: To report a metastatic colorectal cancer patient with hyperbilirubinemia treated with a combination of bevacizumab and FOLFIRI (5-fluorouracil, leucovorin, and irinotecan) using uridine diphosphate glucuronosyl transferase (UGT1A1) genotyping. Clinical Presentation and Intervention: A 46-year-old male was diagnosed with rectosigmoid colon cancer with liver metastases and hyperbilirubinemia presenting with severe jaundice. UGT1A1 genotyping was used before therapy to ascertain whether genotype-adjusted dosages of irinotecan plus bevacizumab could alleviate the toxicity. Then, the patient was treated with FOLFIRI. Conclusion: The FOLFIRI regimen was successfully used in this patient without concerns regarding toxicity.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>24642571</pmid><doi>10.1159/000358799</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1011-7571 |
| ispartof | Medical principles and practice, 2014-01, Vol.23 (5), p.478-481 |
| issn | 1011-7571 1423-0151 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5586907 |
| source | PubMed Central; Karger Open Access |
| subjects | Adenocarcinoma - drug therapy Adenocarcinoma - genetics Adenocarcinoma - secondary Angiogenesis Inhibitors - administration & dosage Antibodies, Monoclonal, Humanized - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab Camptothecin - analogs & derivatives Camptothecin - therapeutic use Case Report Colorectal Neoplasms - drug therapy Colorectal Neoplasms - genetics Colorectal Neoplasms - pathology Fluorouracil - therapeutic use Genotype Glucuronosyltransferase - genetics Humans Hyperbilirubinemia - complications Hyperbilirubinemia - genetics Leucovorin - therapeutic use Liver Neoplasms - drug therapy Liver Neoplasms - genetics Liver Neoplasms - secondary Male Middle Aged |
| title | FOLFIRI Combined with Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer Patients with Hyperbilirubinemia after UGT1A1 Genotyping |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T12%3A24%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=FOLFIRI%20Combined%20with%20Bevacizumab%20as%20First-Line%20Treatment%20for%20Metastatic%20Colorectal%20Cancer%20Patients%20with%20Hyperbilirubinemia%20after%20UGT1A1%20Genotyping&rft.jtitle=Medical%20principles%20and%20practice&rft.au=Yeh,%20Yung-Sung&rft.date=2014-01-01&rft.volume=23&rft.issue=5&rft.spage=478&rft.epage=481&rft.pages=478-481&rft.issn=1011-7571&rft.eissn=1423-0151&rft_id=info:doi/10.1159/000358799&rft_dat=%3Cpubmed_cross%3E24642571%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c494t-ebeb719198bf0a78ac39465fbf5441e9271e4f1decff2f03ee2c7a37bbeb71c23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/24642571&rfr_iscdi=true |